CD38 and Miyoshi myopathy: In subsequent cytotoxicity assays, we showed that daratumumab enhanced NK cell cytotoxicity against the CD38-high MM cell lines, from 20 to 45% for UM9 and from 14 to 33% for RPMI8226/s (Fig. 3).